Tenaya Receives FDA RMAT for Cardiac Gene Therapy TN-401
Tenaya announced regulatory biomarker for heart disease and provided business updates ahead of quarterly data. The stock is expected to react to key interim trial results and pivotal trial guidance, expected by year-end.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed